Health policy experts have missed this 'giant blind spot,' says FDA commissioner

February 6, 2026 - 13:40

In a recent television appearance, FDA Commissioner Dr. Marty Makary pointed to what he describes as a "giant blind spot" in the national conversation on healthcare costs. According to Makary, policy experts and officials have consistently overlooked a critical factor while crafting solutions for high prescription drug prices.

While not delving into specific policy proposals, Makary emphasized the need for a broader perspective that moves beyond traditional regulatory frameworks. He suggested that a key element in creating a more affordable and accessible pharmaceutical market has been absent from mainstream policy discussions for too long.

The commissioner's comments highlight an ongoing and complex debate within the healthcare sector. With medication costs remaining a significant burden for many Americans, identifying all potential avenues for relief is a persistent challenge for lawmakers and health officials alike. Makary's critique implies that effective solutions may require innovative approaches that have yet to be fully explored or implemented on a national scale. The call to address this oversight suggests a potential shift in how regulatory bodies might view their role in fostering price transparency and competition within the drug industry.